Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

This study tests a combination of two targeted drugs — vemurafenib and cobimetinib — for people with high-risk differentiated thyroid cancer that has a specific gene mutation called BRAFV600E. This mutation causes cells to grow uncontrollably, and these drugs are designed to block that pathway. **You may be eligible if...** - You are 18 years old or older - You have thyroid cancer (papillary, follicular, or similar type) confirmed to have the BRAFV600E mutation - Your cancer is high-risk and has not responded to standard treatments - You have adequate organ function (heart, liver, kidneys) **You may NOT be eligible if...** - You do not have the BRAFV600E mutation - You have had prior treatment with BRAF or MEK inhibitors - You have significant heart problems or other serious conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.